GU and hospital-based oncology @UCSFCancer 👉patient decision-making support and survivorship
Joined September 2019
- Tweets 72
- Following 60
- Followers 172
- Likes 201
Photos and videos
Daniel Kwon MD retweeted
30 Apr 2024
🎉 Great work @Kevin_Reyes650, @danielkwonmd and team describing the decision-related needs of people newly diagnosed with #cancer while hospitalized. Multiple perspectives included: patients, caregivers, oncologists.
Check it out: pubmed.ncbi.nlm.nih.gov/3868…
@UCSFCancer @UCSFDHM
2
13
1,756
Daniel Kwon MD retweeted
4 Jun 2023
So excited for @UCSFMedicine 1st year medical student Joy Huang who is an amazing researcher! I’m lucky to have connected with her. 🙌🍀 #ASCO23
2
26
1,367
Daniel Kwon MD retweeted
14 Feb 2023
Skeletal-related events after abiraterone or enzalutamide in patients with #mCRPC: a population-based study using the SEER-Medicare Linked Dataset. #BeyondTheAbstract with @danielkwonmd @UCSFCancer on UroToday > bit.ly/3gO41cw @UrolOncol @mbucknor @HalaBorno
1
2
1,247
27 Jan 2023
A collaborative effort between UCSFs Cancer Genetics and Prevention Program and GU Medical Oncology. @UCSFCancer
27 Jan 2023
A hybrid oncologist/genetic counselor–delivered model is a feasible for high-volume #germlinetesting in men w #prostateCancer #pcSM (both in person & via #telehealth 💻); it does not eliminate racial disparities in testing access however. 👉 fal.cn/3vqSW @danielkwonmd
2
8
1,483
Daniel Kwon MD retweeted
17 Jan 2023
Skeletal-related events after abiraterone or enzalutamide in patients with #mCRPC: a population-based study using the SEER-Medicare Linked Dataset. #BeyondTheAbstract with @danielkwonmd @UCSFCancer on UroToday > bit.ly/3gO41cw @UrolOncol @mbucknor @HalaBorno
1
2
1,017
Daniel Kwon MD retweeted
19 Dec 2022
Skeletal-related events after abiraterone or enzalutamide in patients with #mCRPC: a population-based study using the SEER-Medicare Linked Dataset. #BeyondTheAbstract with @danielkwonmd @UCSFCancer on UroToday > bit.ly/3gO41cw @UrolOncol @mbucknor @HalaBorno
2
2
1,037
6 Oct 2022
Thanks @cancerGRACE for producing this 7-part series I did with Fred on high quality decision making in advanced prostate ca. We talk about why this is important, steps, and resources. Applicable to all cancers! youtube.com/playlist?list=PL…
28 Sep 2022
In this video from our past year's Patient Education Ambassador Program, Dr. @danielkwonmd & Fred discuss his first option: starting hormone treatment immediately and its risks/benefits.
youtu.be/LfcavTfXBiQ
#prostatecancer #cancer #exelixis #lilly #genentech #hormonetherapy
1
2
6 Oct 2022
In this @JAMAOnc Patient Page, we (@AnaVManana @ivandk3) wrote an easy-to-understand explanation of PSMA PET Scans in prostate cancer. jamanetwork.com/article.aspx… Great resource for patients. @cancerGRACE
8
19
Daniel Kwon MD retweeted
4 May 2022
It's rough to wait so long to get 177Lu-PSMA-617 therapy available, and then see a patient who is in such need with a scan that would suggest great benefit (SUVs in the 60s), and then find out that doses can't be delivered for an unknown amount of time. Unbelievable!
13
16
95
Daniel Kwon MD retweeted
23 Mar 2022
Finally! FDA approves 177Lu-PSMA-617. Somewhat odd name (Pluvicto). Can't wait to see the prescribing information.
12
48
257
Daniel Kwon MD retweeted
COVID‐19 outcomes in patients with cancer: Findings from the University of California health system database | @danielkwonmd @FranklinHuang in the journal Cancer Medicine onlinelibrary.wiley.com/doi/… #openaccess
1
2
4
Daniel Kwon MD retweeted
18 Feb 2022
Hey #oncologists and @HemOncFellows! We’re recruiting a new @UCSFHospitals hospital-based oncologist (#HBO)! Come join our growing inpatient solid onc group w @danielkwonmd and me @UCSFCancer 🥰
Apply: bit.ly/HBOfacultyrecruit
Why I ❤️ #HBO: bit.ly/HBOtheOncologist
🩺🥼🏥🥰
7
22
Daniel Kwon MD retweeted
3 Feb 2022
mercurynews.com/2022/02/03/8… thanks to the Mercury News for publishing my reflection on what doctoring has taught me about processing the irreplaceable losses of the pandemic.
3
1
13
Daniel Kwon MD retweeted
27 Jan 2022
Hiring AHP (NP/PA) for @UCSFCancer hospital-based oncology #HBO service! Internal and external AHPs welcome: bit.ly/UCSFNPint bit.ly/UCSFNPext bit.ly/UCSFPAint bit.ly/UCSFPAext
Work w sweet (@danielkwonmd) and sassy (🙋🏻♂️) attendings 😝 @UCSFHospitals
5
13
Daniel Kwon MD retweeted
12 Jan 2022
Two years into the #COVID19 pandemic & we are still worrying about all the missed #hemeonc fellow professional & career development opportunities!
Excited to see our work in @JCOOP_ASCO ascopubs.org/doi/full/10.120…
highlighting PD #burnout & perspectives on #fellowship needs
6
30
97
8 Jan 2022
Thanks for highlighting our work. @UCSFCancer
7 Jan 2022
A mobile application for pts to record consults was feasible, acceptable, and a potentially valued intervention to improve decision making in the #telehealth setting for men w/ #prostatecancer. fal.cn/3l9BG #pcsm #JCOOP @danielkwonmd
2
11
Daniel Kwon MD retweeted
7 Jan 2022
A mobile application for pts to record consults was feasible, acceptable, and a potentially valued intervention to improve decision making in the #telehealth setting for men w/ #prostatecancer. fal.cn/3l9BG #pcsm #JCOOP @danielkwonmd
6
14
7 Dec 2021
Great work by @WaspGarrett. Used consultation audio recordings of pt-oncologist visits to find that when discussing systemic tx, default is to continue tx, 2/2 deficiencies in shared decision making. What can be done? ascopubs.org/doi/abs/10.1200…
1
1
4
7 Dec 2021
Need to increase our visit times, implement communication tools like consultation recordings, decision tools like decision aids and question prompt lists, and make sure our workforce has adequate, culturally competent communication training. @JCOOP_ASCO
2
Daniel Kwon MD retweeted
26 May 2021
Thank you @JournalCancer for highlighting work with @danielkwonmd @HemoncUcsf of outcomes in mCRPC patients with DDR mutations, a multi-institutional effort @UCSFCancer @UCSFMedicine @UMRogelCancer @UBCmedicine @PCFnews @PCF_Science
25 May 2021
Read our June 15 issue today! 📗
acsjournals.onlinelibrary.wi…
In this issue:
➡️ @koshkin85 et al on differential tx outcomes in mCRPC
➡️ @BrainMets_MSK investigators on MBMs in the age of adv treatments
➡️ @DrFadloKhuri's reflection on the past 10 years as our Editor-in-Chief
6
14